Chronic idiopathic urticaria with functional autoantibodies: 12 years on.
It is now recognized that approximately one-third of patients with chronic idiopathic urticaria (CIU) have histamine-releasing autoantibodies directed against either the high-affinity IgE receptor or, less frequently, against IgE. However, there are several unsolved problems relating to the role of such autoantibodies in the disease. Additionally, it is not clear whether CIU with autoantibodies can be classified as an autoimmune disease. The detection of patients with autoantibodies also poses challenges. Firstly, the only in vivo method, the autologous serum skin test, is at best 80% sensitive and specific using in vitro basophil histamine release assays as the verum. Secondly, in vitro tests are only done in a small number of research laboratories, and are not widely commercially available, and thirdly, there is some divergence between results obtained by different methods (functional and immunoassays) used to detect patients with autoantibodies. The presence of autoantibodies may be important clinically in a small group of severely affected, treatment-resistant patients, where immunomodulatory treatments may be helpful.
Sabroe
R A
RA
Department of Dermatology, Barnsley Hospital NHS Foundation Trust, Gawber Road, Barnsley S75 2EP, UK. rsabroe@doctors.org.uk
Greaves
M W
MW
D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use; D006636:Histamine Release; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D017455:Receptors, IgE / Q000276:immunology; D014581:Urticaria / Q000188:drug therapy / Q000276:immunology*
D001323:Autoantibodies; D003879:Dermatologic Agents; D017455:Receptors, IgE; D007073:Immunoglobulin E